Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies

Ron J. Keizer,1,6 Y. Funahashi,2 T. Semba,3 J. Wanders,4 J. H. Beijnen,1,5 J. H. M. Schellens,4,5 and A. D. R. Huitema1

Received 17 August 2010; accepted 4 February 2011; published online 9 March 2011

Abstract. E7820 is an orally active inhibitor of α2-integrin mRNA expression, currently tested in phases I and II. We aimed to evaluate what levels of inhibition of integrin expression are needed to achieve tumor stasis in mice, and to compare this to the level of inhibition achieved in humans. Tumor growth inhibition was measured in mice bearing a pancreatic KP-1 tumor, dosed at 12.5–200 mg/kg over 21 days. In the phase I study, E7820 was administered daily for 28 days over a range of 0–200 mg, followed by a 7-day washout period. PK-PD models were developed in NONMEM. α2-Integrin expression measured on platelets, corresponding to tumor stasis at t=21 in 50% and 90% of the mice (inh,50, inh,90) were calculated. It was evaluated if these levels of inhibition could be achieved in patients at tolerable doses. One hundred nineteen α2-Integrin measurements and 210 tumor size measurements were available from mice. The relationship between PK and α2-integrin expression was modeled using an indirect-effect model, subsequently linked to an exponential tumor growth model. inh,50 and inh,90 were 14.7% (RSE 7%) and 17.9% (RSE 8%). Four hundred sixty two α2-integrin measurements were available from 29 patients. Using the schedule of 100 mg qd (MTD), α2-integrin expression was inhibited more strongly than the inh,50 and inh,90 in greater than 95% and greater than 50% of patients, respectively. Moderate inhibition of α2-integrin expression corresponded to tumor stasis in mice, and similar levels could be reached in patients with the dose level of 100 mg.qd.

KEY WORDS: biomarker; E7820; modeling and simulation; oncology; pharmacodynamics.

INTRODUCTION

The investigational anti-cancer drug E7820 is an orally active angiogenesis inhibitor, and has shown anti-tumor activity in several tumor models in mice, the effect of which was mediated through the inhibition of expression of α2-integrin (1,2). Integrins are receptors that mediate attachment between cells, and between cells and the extracellular matrix (3). They also play an important role in cell signaling. Many types of integrins have been identified, multiple types may be expressed on the cell surface simultaneously. Integrins are heterodimers, consisting of α (alpha) and β (beta) subunits. In mammals, 18 α and 8 β subunits have been characterized, with varying functions related to cell attachment and cell signaling. It has been shown in preclinical experiments that suppression of integrin α2 by E7820 played a crucial role in inhibition of endothelium tube formation (1,2). E7820 was evaluated in a phase I dose escalation study in patients with malignant solid tumors or lymphomas, the clinical results of which have been reported previously (4) and for which a population PK model was presented before (5). Since α2-integrin is expressed both on tumor cells and on platelets, it has been hypothesized that α2-integrin expression on platelets may be an easily evaluable biomarker for tumor growth inhibition in response to treatment with E7820 (1,2).

The inhibition of α2-integrin measured on platelets provides a measure of pharmacological target modulation, and therefore would theoretically provide a better predictor of activity than measures of E7820 plasma exposure. α2-Integrin is therefore currently being evaluated in phase I studies as possible biomarker (4,6). In this article, we present a modeling and simulation analysis that integrates data from preclinical experiments and a phase I clinical trial to evaluate the expected efficacy of the dose levels that were studied in phase I. Similar analyses have been presented earlier for the development of everolimus (7) and gefitinib (8). The aim of
the analysis was to establish levels of integrin inhibition in humans which corresponded to inhibition levels associated with tumor stasis in mice. Therefore, we first aimed to establish what level of α2-integrin inhibition corresponds to tumor stasis in mice. This was done by establishing PK-PD models for the preclinical experiments, describing the relationships between E7820 plasma exposure, the inhibition of α2-integrin expression, and tumor growth inhibition. Subsequently, we investigated if the dose regimen proposed from the phase I study based on acceptable toxicity would result in sufficient inhibition of α2-integrin expression to expect anti-tumor activity in patients. For this, a model was constructed describing effects of exposure to E7820 on α2-integrin expression. This model was based on the human PK model and measurements of α2-integrin during the phase I trial. Finally, it was evaluated whether clinical regimens were capable of achieving inhibition of α2-integrin expression in humans similar to that which led to tumor stasis in mice. It was thus assumed that a similar level of α2-integrin expression would be required for tumor growth inhibition in mice and humans, for tumors that are sensitive to angiogenesis inhibition mediated by α2-integrin.

METHODS

Preclinical Experiments

The PK profile of E7820 in female KSN Slc mice aged 6, 7, or 8 weeks was elucidated after single IV (25 mg/kg, n=3), single oral (25, 50, and 100 mg/kg, n=4), and seven repeated oral administrations with about 12 h intervals (50 mg/kg, n=4). Concentrations of E7820 in plasma were obtained using a validated liquid chromatography method with UV detection, with precision >15% over the entire concentration range. Mean PK parameters CL, V, and F were calculated by non-compartmental analysis. The tumor growth experiments in mice have been described before (1). Briefly, a human pancreatic carcinoma cell line (KP-1, 5×10^6 cells/head) was transplanted subcutaneously into 7-week old female nude mice. Administration of E7820 was started at doses of 12.5, 25, 50, 100, or 200 mg/kg, or vehicle, 1 week after the transplantation. E7820 was administered orally by gavage, twice a day for 3 weeks. PK samples were collected twice weekly. Blood was withdrawn once a week from the eye of anesthetized mice in PBS containing 0.004% sodium citrate and diluted at 1:100. Diluted blood samples were directly stained with FITC-conjugated anti-integrin α2 Ab and expression levels on platelets were analyzed by flow cytometry. The longest diameter of the tumor and body weight was measured twice a week by direct measurement of the tumor diameters with calipers.

Software

The statistical data analysis and simulations were performed with non-linear mixed-effects modeling using NONMEM, version VI, level 2.0 (Icon Development Solutions, Ellicott City, MD, USA) with gfortran (http://gcc.gnu.org/gfortran/) as Fortran compiler, and Piraha (9) as modeling environment. The first-order conditional estimation method with interaction (FOCE-I) was used throughout the model building. Standard errors for model parameters were estimated using the covariance step in NONMEM. Model evaluation and selection was based on objective function value (p level of 0.01, ∆OFV=6.63 was considered a significant improvement in fit), successful convergence, goodness-of-fit plots and visual predictive checks (10). R (version 2.9.0, http://www.cran.r-project.org) was used for the analysis of simulated data, and the generation of plots. Modeling and simulation were performed according to a pre-specified analysis plan, and construction of the PK-PD model was performed sequentially. First, the effect of E7820 plasma concentrations was correlated with the inhibition of α2-integrin expression. Next, a tumor growth model based on the unperturbed tumor growth experiment was fitted. The parameter estimates for the α2-integrin model were then fixed, and the model predicted expression levels were used to drive the different tumor growth models that were evaluated.

Integrin Expression in Mice

Longitudinal description of the α2-integrin expression level on platelets was modeled as an indirect response model (11) with an inhibitory effect on input rate (k_in) of E7820 plasma concentration, described by a linear equation or by the Hill equation:

\[
\frac{dI}{dt} = \frac{k_{in}}{1 + \frac{E_{max,I}}{IC_{50,I}} + I} - k_{out} \cdot I
\]

in which I describes the relative integrin expression, k_in and k_out are the input and output rates of the indirect-effect model. The plasma concentration of E7820 was defined as c_p, and E_{max,I}, IC_{50,I} and γ were the maximal drug effect, the plasma concentration at half maximal effect, and the shape exponent of the Hill equation describing the drug effect on the α2-integrin expression rate, respectively. An inhibitory effect of plasma exposure on k_in was considered a mechanistically more plausible model than a stimulatory effect on k_out as the pharmacological effect of E7820 is mediated through the inhibition of mRNA expression. α2-Integrin expression at baseline (I_0) was estimated (12). To allow for hysteresis in drug effects on α2-integrin, the inclusion of one or more effect compartments was tested. It was also assessed if development of tolerance to E7820 could be shown.

Tumor Growth in Mice

Two prerequisites for the tumor growth model were established: the model should be able to (a) capture the unperturbed growth, and (b) capture the inhibitory effect of decreased α2-integrin expression on tumor growth/shrinkage rate, over the entire dose range of E7820. Several tumor growth models were evaluated, including exponential models, Gompertz models (13), and a tumor growth model introduced by Simeone et al. (14). Linear and E_{max} relationships were evaluated for their ability to correlate the effect of inhibition of α2-integrin expression to one of the relevant growth rate parameters in the tumor growth models. For both the model for α2-integrin and the tumor growth model, it was evaluated if the available data supported the estimation of between
subject variability (BSV) of the parameters. For both models, exponential residual error model were used.

Calculation of Efficacious $\alpha_2$-Integrin Inhibition

Using stochastic simulations from the preclinical PK-PD model, it was investigated what level of inhibition of expression of $\alpha_2$-integrin correlated with tumor stasis. Achieving tumor stasis at $t=21$ days (end of treatment period in preclinical experiments) in 50% or 90% of mice were defined as targets. The inhibition of $\alpha_2$-integrin expression ($I_{\text{inh},av}$) at steady state was chosen as the measure of inhibition of $\alpha_2$-integrin expression required to achieve these goals. The simulations were performed for dose levels varying from 50 to 200 mg/kg with 20-mg/kg intervals, and each simulations was performed for 500 mice. In each simulation, the percentage of mice having tumor sizes less than or equal to their baseline tumor sizes was recorded, along with the $I_{\text{inh},av}$. From the results of the simulations, relationships between dose level, $\alpha_2$-integrin inhibition and tumor growth inhibition at $t=21$ were plotted, and the $I_{\text{inh},av}$ values at which 50% and 90% of mice achieved tumor stasis were calculated ($I_{\text{inh},50}$ and $I_{\text{inh},90}$). To account for uncertainty in model parameter estimates, and to calculate relative standard errors (RSE) for these targets, these simulations were repeated 250 times with parameters sampled from the variance–covariance matrix obtained for the model.

Clinical Trial Data

E7820 was administered to patients daily for 28 days, followed by a washout period of 7 days prior to starting subsequent cycles. Blood samples were collected from 1 up to 9 treatment cycles. Bioanalysis of PK was performed using the same method as used for the preclinical samples. Blood samples for $\alpha_2$-integrin expression were determined from blood collected at predose, and at 6 h post-drug administration on day 1, predose on day 28 of cycle 1 and at 24 h post-drug administration. Beyond cycle 1 and for each subsequent cycle, blood was collected on day 28 predose. Diluted blood samples were directly stained with FITC-conjugated anti-integrin $\alpha_2$ Ab and expression levels on platelets were analyzed by flow cytometry, and expressed in molecules of equivalent soluble fluorochrome.

Modeling of Clinical Data

Previously, a population PK model was constructed from data from the phase I trial (Table I) (5). This model was used here as well, however, to avoid difficulties arising from incorporation of multiple dosing in the turnover absorption model, the absorption model was simplified to a first-order absorption model. The empirical Bayesian estimates (EBEs) for oral clearance (CL/F) and volume of distribution (V/F), and typical parameter values for $ka$ obtained from this PK model and the observed data were used to drive the PD model for $\alpha_2$-integrin expression. Within-subject variability in PK parameters was disregarded in the PD analysis. For the clinical data, a similar indirect-effect model for the inhibition of $\alpha_2$-integrin expression was evaluated as was used for the preclinical data. It was evaluated if the available data supported the estimation of BSV on the PD parameters. Dosing regimens of 50, 70, 100, and 200 mg qd were then simulated using the developed model to investigate the expected inhibition of $\alpha_2$-integrin expression during continuous treatment at these levels. These simulations were performed in 1,000 patients, to account for inter individual variability in response to E7820. The relative $\alpha_2$-integrin inhibition at steady state was calculated (two cycles), which was compared to the $I_{\text{inh},av}$ that was required for tumor stasis calculated from the preclinical data.

RESULTS

PK in Mice

In the PK experiments in mice, elimination half-life was 0.63 h and a low plasma clearance (CL=$7.85\ \text{mL min}^{-1}\ \text{kg}^{-1}$) and low volume of distribution ($V=0.684\ \text{L/kg}$) after IV dosing of E7820 were observed. The observed PK profiles after IV administration were monophasic, and a linear increase of AUC was observed from 25 to 100 mg/kg after a single oral dose. As the absorption was rapid with $t_{\text{max}}$ at $\sim1$ h, an absorption rate (ka) of 3 h$^{-1}$ was used throughout. Plasma protein binding of E7820 was concentration independent from 5 to 100 mg/L, and was 89% (range 88.0–90.2%). Mean bioavailability after oral administration of 25 mg/kg was 61.3%. E7820 showed anti-tumor activity at doses of 50, 100, and 200 mg/kg in the tumor growth and $\alpha_2$-integrin expression experiments.

Integrin Inhibition in Mice

The exposure–response relationship between E7820 plasma concentration and the inhibition of input rate of the turnover model was significantly better described using an $E_{\text{max}}$-equation than when using a linear relationship. An $E_{\text{max}}$ value of 1.1 (RSE 36%) was estimated, but was not significantly different from 1. Likely, due to the fact that $\alpha_2$-integrin expression was inhibited maximally by only 30%, a sigmoidal $E_{\text{max}}$ model could not be estimated. Therefore, the

| Table I. Characteristics of Clinical Phase I Study (4) |
|-----------------|-----------------|
| Total number of patients | 36 |
| Dose level | Value (range) |
| 10 mg | 3 |
| 20 mg | 4 |
| 40 mg | 3 |
| 70 mg | 3 |
| 100 mg | 17 |
| 200 mg | 6 |
| Sex | Value (range) |
| Male | 20 |
| Female | 16 |
| Race | Value (range) |
| Caucasian | 31 |
| Black | 1 |
| Hispanic | 4 |
| Weight (kg) | 70.9 (43.2–113.6) |
| Height (cm) | 167.3 (150.5–182.9) |
| BSA (m$^2$) | 1.805 (1.375–2.402) |
| Age (years) | 64.8 (40.0–82.0) |

Continuous variables given as mean (range) and categorical data as counts.
shape parameter $\gamma$ in the Hill equation was fixed to 1, reducing the exposure–response relationship to a non-sigmoid $E_{\text{max}}$ model. The inclusion of delay in the effects of drug exposure on $\alpha_2$-integrin expression did not significantly improve model fit, nor did the inclusion of a term describing resistance to the inhibition of $\alpha_2$-integrin expression by E7820. Figure 1 shows a visual predictive check of the model describing $\alpha_2$-integrin expression, which indicated adequate model fit.

**Tumor Growth in Mice**

Although all evaluated tumor growth models were able to describe unperturbed growth, only when an exponential model was used could the effects of integrin inhibition be captured adequately over the entire dose range studied in the preclinical experiments. In the exponential model, it was however necessary to include an adjustment for the observed initial slow tumor growth, since almost no tumor growth or even tumor shrinkage in some mice (receiving only vehicle) was observed in the first week. This was captured by including a mono-exponential term describing an initially complete and gradually decreasing resistance to tumor growth, on top of the basic exponential tumor growth differential equation:

$$\frac{dT}{dt} = \alpha \cdot (1 - e^{-\beta t}) \cdot T$$

with $T$ describing the tumor size in mm, $\alpha$ describing the tumor growth rate, $\beta$ being the rate of decline of initial resistance to maximal unperturbed tumor growth, and $t$ being the time in days after start of treatment. The inhibitory effect of decreased $\alpha_2$-integrin expression on tumor growth was incorporated as a sigmoidal $E_{\text{max}}$ function, implemented relative to current tumor size:

$$\frac{dT}{dt} = \alpha \cdot (1 - e^{-\beta t}) \cdot T - \frac{E_{\text{max},T} \cdot E_{\text{inh},T}}{E_{50,T} + E_{\text{inh},T}} \cdot T$$

$E_{\text{max},T}$, $E_{50,T}$ and $\gamma$ are the maximal effect of inhibition of $\alpha_2$-integrin expression, the plasma concentration at half maximal effect, and the Hill coefficient, respectively. The Hill coefficient could not be estimated, and was therefore fixed at 5 to allow sigmoidicity in the relationship. This provided significantly better fit than using the non-sigmoidal form. The inclusion of a delay between the effect of $\alpha_2$-integrin inhibition on tumor growth did not result in a significantly better model fit. All parameters could be estimated with reasonable precision, except the parameters describing unperturbed growth. The high uncertainty (>100%) in estimation of these parameters could be explained by the fact that these estimates were obtained by fitting only the tumor growth data from the five mice that received vehicle and no drug. A visual predictive check, shown in Fig. 2, however showed that the model described the observed data accurately for these mice, and also for the other mice, when the effects of decreased $\alpha_2$-integrin expression were incorporated in the model.

A schematic representation of the structural model describing the tumor growth inhibition and $\alpha_2$-integrin expression is shown in Fig. 3, and parameter estimates for the PK-PD model are presented in Tables II, III, and IV. The tumor growth model was able to describe the tumor growth in
the mice with adequate precision for all dose levels, as can be seen in the plots in Fig. 2 which show both the observed tumor growth curves and the 80% of model predictions (i.e. between-mice variation in tumor size, and inhibition of tumor growth rates). The plots reveal that tumor growth was considerably inhibited from doses of 50 mg/kg upward, but that tumor stasis (relative to baseline) at \( t=21 \) was only achieved at doses of 100 and 200 mg/kg. In Fig. 4, the relationships between dose level, inhibition of \( \alpha_2 \)-integrin expression, and tumor growth inhibition are plotted, which were calculated from simulated tumor growth experiments. The inhibition of \( \alpha_2 \)-integrin expression at steady state that is required for tumor stasis in 50% and 90% of mice (\( I_{inh,50} \) and \( I_{inh,90} \)) were calculated to be 14.7% (RSE 7%) and 17.9% (RSE 8%), respectively.

**Analysis of Clinical Trial Data**

In total, 462 \( \alpha_2 \)-integrin level measurements at 209 unique timepoints were available from 29 patients with solid tumors or lymphoma. The same turnover model that was used in the preclinical experiments was used to describe the \( \alpha_2 \)-integrin profiles observed in the clinical trial. It was observed that the estimate for the turnover rate parameter (\( k_{out} \)) in the clinical model (0.099) was fairly similar to the estimate for the preclinical model (0.143), suggesting that rates of integrin inhibition are comparable, and only slightly faster in the preclinical setting. The estimate for IC\(_{50}\) value obtained for the clinical model was about fourfold higher than obtained for the preclinical model. Although BSV in baseline levels

---

**Fig. 2.** Tumor growth curves in mice with implanted KP-1 tumors at different dose levels of E7820. The *thin solid lines* indicate observed growth curves, the *black solid* indicates model predicted growth curve, and the *gray area* indicate the 80% confidence interval of the model predictions.

**Fig. 3.** Structure of the preclinical PK-PD-tumor growth model. The clinical model had the same structure, but did not incorporate a sub-model for tumor size.
Dose Evaluation E7820 Using Biomarker

and drug sensitivity were high, significant effects of plasma drug exposure on the inhibition of α2-integrin expression were observed, and an $E_{\text{max}}$ model best described this relationship. The data allowed the estimation of BSV in baseline α2-integrin expression levels and drug sensitivity (IC50). A delay in drug effect did not improve the model, nor did a model that incorporated development of tolerance to E7820. Figure 5 shows a visual predictive check of the model and the data, in which dose levels of less than or equal to 50 mg qd, and dose levels of greater than or equal to 70 mg were grouped. This figure shows that the observed profiles correspond to the median model predicted profiles, and that most of the observed profiles are contained within the 90% confidence interval of the model predictions.

Simulations of Clinical Regimens

In Fig. 6, the results of simulations for the four highest dose levels that were studied in the phase I trial are plotted, along with the steady state level of α2-integrin expression inhibition corresponding to tumor stasis in 50% and 90% of mice. In Table V, the average inhibition of α2-integrin expression ($I_{\text{inh,av}}$) after one cycle of E7820 of 28 days in patients is shown. These results demonstrate that a regimen of 50 mg qd is expected to result in less than 50% of patients achieving the defined target of both $I_{\text{inh,50}}$ and $I_{\text{inh,90}}$. At continuous dosing at 70 mg qd, inhibition of α2-integrin expression is expected to achieve the $I_{\text{inh,50}}$ target in >50% of patients, but the median expected integrin level is slightly lower than the $I_{\text{inh,90}}$. At doses of 100 mg qd, median inhibition is higher than both targets, although the 95% confidence interval was not entirely higher than the $I_{\text{inh,90}}$ target. Only at the highest evaluated but toxic dose of 200 mg qd are 95% of patients expected to achieve inhibition of expression higher than both targets. This dose level has however been shown to induce non-tolerable hematological toxicity (15).

DISCUSSION

We have presented here a first population PK-PD analysis of preclinical and clinical data of the α2-integrin inhibitor E7820, and evaluated relationships between exposure to E7820, α2-integrin expression and tumor growth. Integrin inhibitors have been introduced recently as potential new treatment modalities in anti-cancer treatment that inhibit tumor growth by inhibiting angiogenesis. Integrins are heterodimer transmembrane receptors that are essential factors in angiogenesis as they mediate endothelial cell migration, proliferation and survival (16). Preclinical studies have shown that the inhibition of integrins, either by

Table II. PK Model Parameters Based on the Preclinical and Clinical Studies

| Parameter          | Preclinical (mice) Estimates (IB) | Clinical Estimates (5) | RSE |
|--------------------|-----------------------------------|------------------------|-----|
| PK                 |                                   |                        |     |
| CL* a              | Clearance                         | 0.471 L h$^{-1}$ kg$^{-1}$ | 6.24 L h$^{-1}$ | 5%  |
| V                  | Volume of distribution            | 0.684 L kg$^{-1}$      | 66.0 L     | 8%  |
| F                  | Oral bioavailability              | 69.3 %                 | –          |     |
| ka                 | Absorption rate                   | $3^b$ h$^{-1}$         | 0.889 h$^{-1}$ | 7%  |
| $\sigma_{CL}$      | BSV in clearance (CV)             | –                      | 51 %       | 12% |
| $\sigma_V$         | BSV in volume of distribution (CV)| –                      | 48 %       | 17% |
| $\rho_{CL-V}$      | Correlation $CL-V$ (CV)           | –                      | 62 %       | 12% |

$^a$ Clinical estimates for clearance and volume of distribution are given as CL/F and V/F.$^b$ Absorption rate unknown, but assumed rapid (3 h$^{-1}$) in preclinical experiments ($t_{\text{max}}$ was observed at ~1 h). BSV: between subject variation, RSE: Relative standard error (%), CV: coefficient of variation (%).

Table III. PD Model Parameters for Integrin Model Based on the Preclinical and Clinical Studies

| Parameter                        | Preclinical (mice) Estimates | Clinical Estimates | RSE |
|----------------------------------|------------------------------|-------------------|-----|
| PD: α2-integrin model            |                              |                   |     |
| $I_{\text{base}}$               | Baseline integrin level      | 22.5 % (1%)        | 8,350 MESF | 1%  |
| $K_{\text{in}}$                 | Input rate turnover model    | 3.21 %day$^{-1}$ (19%) | 825.6 MESF day$^{-1}$ | 14% |
| $K_{\text{out}}$ a              | Output rate turnover model   | 0.143 day$^{-1}$  | 0.099 day$^{-1}$ |     |
| $E_{\text{max},C}$             | Maximal effect of E7820     | 1 a                | 1 a            |
| $IC_{50}$                        | Concentration at 50% of maximal effect | 656 ng ml$^{-1}$ (18%) | 2,840 ng ml$^{-1}$ | 32% |
| $\omega_{I_{\text{base}}}$      | BSV in integrin baseline     | 31 % (40%)         | 40.0 % | 19% |
| $\omega_{\text{eff}}$           | BSV in sensitivity to E7820 | –                  | 110 % | 32% |
| $\sigma_{\text{exp}}$           | Exponential residual error (CV) | 6.7 % (8%)          | 11.5 % | 23% |

MESF: molecules of equivalent soluble fluorochrome

$^a$ Fixed

$^b$ Not estimated, but calculated as $I_{\text{base}}/K_{\text{in}}$
monoclonal antibodies, peptide drugs, or small molecules can result in tumor remission (16,17). Currently, integrin inhibitors are investigational drugs and are in clinical and preclinical testing as single agents or in combination with other anti-cancer agents.

From experiments in mice, we were able to model with good accuracy the effects of drug exposure on levels of $\alpha_2$-integrin inhibition and tumor growth suppression in mice. The inhibition of $\alpha_2$-integrin expression levels was described by an indirect-effect model, which is the most widely used pharmacodynamic model for describing physiological processes. The model was able to describe the decrease in $\alpha_2$-integrin expression over time in response to treatment with E7820 and account for the between-mice variation in drug response. A simple exponential tumor growth model was then used to describe tumor growth profiles in mice; with the predicted $\alpha_2$-integrin expression levels driving growth inhibition A Gompertz model (13) provided worse fit than the empirical exponential model. Although tumor growth models have been presented in literature that is somewhat more physiologically based than the exponential model (14,18), this model could also not describe our tumor growth better than the exponential model. More importantly, as the aim of this study was not to scale or extrapolate the tumor growth model to other species or other drugs, but primarily in accurately describing the relationship between $\alpha_2$-integrin expression and tumor growth, the exponential model was deemed most adequate. It should be stressed that the term $\left(1 - e^{-\beta t}\right)$ included in the model does not describe drug resistance but rather initial slow tumor to growth, and that the rate parameter $\beta$ was estimated solely based on the unperturbed growth curves. The initial slow growth rate may be due to the transplanted tumor not being fully embedded yet in the tumor environment, and thus not fully able to receive nutrients and oxygen needed for growth. Although administration of E7820 started 7 days after transplantation of the tumor, this period may thus not be long enough to achieve the full potential tumor growth rate. It was noticed that $t_{1/2}$ was much lower in mice than in humans (1.01 h versus 7.33 h). Additionally, relatively higher doses were administered to

### Table IV. PD Model Parameters for the Tumor Growth Model Based on the Preclinical and Clinical Studies

| Parameter | Preclinical (mice) |
|-----------|--------------------|
| $T_{\text{base}}$ | Baseline tumor size | 5.14 mm | 1% |
| $\alpha$ | Maximal exponential growth rate | 0.0903 day$^{-1}$ | 103% |
| $\beta$ | Rate of initial resistance to tumor growth | 0.0391 day$^{-1}$ | 130% |
| $E_{\text{max,}I}$ | Maximal effect of integrin inhibition on tumor growth | 0.0472 day$^{-1}$ | 5% |
| $II_{50}$ | Relative inhibition of integrin expression at 50% of maximal effect | 11.4 % | 6% |
| $\omega_{\text{base}}$ | BSV in baseline tumor size | 6 % | 13% |
| $\omega_{II_{50}}$ | BSV in sensitivity to integrin expression inhibition | 20 % | 50% |
| $\sigma_{\text{exp}}$ | Exponential residual error (CV) | 6 % | 6% |

![Fig. 4. a–c. Relationships between dose level, relative integrin inhibition at steady state, and relative tumor size measured in the tumor growth experiments in mice at t=21 days. Solid line indicates median, gray area indicates 90% prediction interval (variation between mice)](image-url)
mice than humans (maximum doses 200 mg/kg in mice vs 200 mg in humans). Therefore, much higher $C_{\text{max}}$ concentrations were reached in mice, although E7820 was cleared faster. This may be important: apparently higher concentrations were required in mice compared to humans to elicit a response in integrin expression. However, inhibition of integrin expression in patients was already observed at the MTD of 100 mg, and therefore higher doses were not required to achieve pharmacological activity.

Using simulations from the combined preclinical model for E7820 exposure, $\alpha_2$-integrin and tumor growth, targets were estimated. The PK-PD model describing the relationship between E7820 exposure and $\alpha_2$-integrin expression in patients was then used to evaluate if these targets could be met with the regimens that were investigated in the clinical trial. This analysis showed that only at the highest toxic dose

---

**Fig. 5. a–b.** Visual predictive check of the PK-PD model for $\alpha_2$-integrin expression on platelets in patients, for dose levels of $\leq$50 mg qd (a), and $\geq$70 mg qd (b). The thin solid lines show the individual observed integrin expression levels. Thick solid lines indicate model predicted median integrin expression over time, while the gray area indicates the 90% interval of the predicted between patient variation.

**Fig. 6.** Expected $\alpha_2$-integrin expression profiles (relative to baseline, without residual variability) during four continuous dosing regimens (qd). Solid lines indicate median expected $\alpha_2$-integrin expression levels, gray areas indicate the 90% model prediction intervals. Dotted and dashed lines indicate the $I_{\text{inh},50}$ and $I_{\text{inh},90}$ (the average daily $\alpha_2$-integrin expression inhibition needed for 50% and 90% of mice to reach tumor stasis, respectively).
have shown that the expression is constant over time (1) and analysis of the data from the clinical study shows that relative \( \alpha \) inhibition of \( \alpha \)-integrin expression, the proposed dose of 100 mg qd is likely to achieve sufficient inhibition of \( \alpha \)-integrin expression to achieve tumor growth inhibition. Based on this analysis, doses of 50 mg qd or lower are however unlikely to achieve efficacy.

This analysis provides evidence to support the notion that relative \( \alpha \)-integrin expression as measured on platelets may serve as a clinical biomarker for treatment efficacy. Considerable variation in baseline \( \alpha \)-integrin expression was observed between patients, thereby diminishing the predictive performance of absolute expression levels. However, limited experiments in healthy volunteers have shown that the expression is constant over time (1) and analysis of the data from the clinical study shows that expression remained constant in patients receiving low doses of E7820. A significant effect of drug exposure on the inhibition of \( \alpha \)-integrin expression was found. This suggests that the level of \( \alpha \)-integrin expression as measured on platelets relative to the baseline level could serve as a biomarker to assess target modulation in response to treatment with E7820. Since the \( \alpha \)-integrin inhibition targets obtained from the preclinical experiments were low (<20%), this suggest that even moderate inhibition of \( \alpha \)-integrin expression on platelets is correlated with tumor growth inhibition.

In the development of new drugs, results from preclinical efficacy and toxicity experiments are generally only used to serve as input for the early clinical stage, *i.e.*, to provide a safe starting dose. Once in the clinical stage, results from preclinical efficacy experiments, *i.e.*, tumor growth experiments, are often not taken into account. In this analysis, in contrast, we present an integrated model-based analysis of all data currently available on E7820: data obtained from preclinical experiments were projected onto data obtained from a clinical trial. As data from the preclinical stage may hold valuable information on the *in vivo* drug response, especially when combined with data on a suitable pharmacodynamic biomarker, such an analysis may allow an early assessment of efficacy.

It is currently unknown how different tumor types will respond to E7820 exposure, and to the inhibition of integrin expression. It is also not clear yet which tumor types respond best to this compound. Likely, not all tumor types will be sensitive to the inhibition of integrin, and therefore the value of integrin expression as a biomarker must be assessed in more detail in subsequent studies. The preclinical PD model was built using data obtained using a pancreatic cell line. If more preclinical data would become available, the model could be updated with other cell-lines as well, to provide a more robust model, or a model tailored to specific tumor types. Another important consideration with this analysis is the role that integrins play in mouse compared to humans. In the preclinical experiments, integrins on platelets were of mouse origin, while those on tumor were of human origin. How this impacts the results is unclear, and calls for caution in interpretation of the results. Another consideration is that tumor growth rates and integrin turnover rates may differ between mice and humans. Additionally, as in patients, larger, necrotic, and more variably sized tumors are encountered and blood supply to tumors is likely to differ between the two species. Further clinical investigation is therefore needed to confirm the results of this analysis. Additional biomarker and tumor growth collected from a homogeneous group of patients will allow refinement of the current model, and will establish validity of \( \alpha \)-integrin as a biomarker for tumor growth inhibition. However, in our opinion, the analysis presented here is the most informative analysis that is possible at the current stage of development of this drug, as it not only takes into account the clinical results but also results from the preclinical phase.

### Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

### REFERENCES

1. Sembia T, Funahashi Y, Ono N, *et al.* An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. Clin Cancer Res. 2004;10:1430–8.

2. Funahashi Y, Sugi NH, Sembia T, *et al.* Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res. 2002;62:6116–23.

3. Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR, Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol. 2002;160:195–204.

4. Mita MM, Mitra AC, Goldston M, *et al.* Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: results of a phase I study. J Clin Oncol (Meeting Abstracts). 2005;23:3082.

5. Keizer RJ, Zamacona M, Jansen M, *et al.* Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820 [Internet]. Investigational New Drugs 2008[cited 2008 Aug 25] Available from: http://www.ncbi.nlm.nih.gov/pubmed/18712503.

6. Sawyer MB, Iqbal S, Lenz H, *et al.* Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC). J Clin Oncol (Meeting Abstracts). 2010;28:3537.

7. Tanaka C, O’Reilly T, Kovarik JM, *et al.* Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008;26:1596–602.

### Table V. Expected Relative Integrin Expression Inhibition \( (I_{inh,\alpha}) \) at Steady State, Obtained from Simulations of Clinical Dosing Regimens

| Dosing regimen | Expected \( I_{inh,\alpha} \) at \( t=21 \) (CI 95%) |
|----------------|-----------------------------------------------|
| 50 mg qd       | 12.8% (9.1%–17.7%)                            |
| 70 mg qd       | 17.2% (11.9%–23.3%)                           |
| 100 mg qd      | 23.0% (16.5%–30.2%)                           |
| 200 mg qd      | 37.8% (29.1%–48.0%)                           |
8. Wang S, Zhou Q, Gallo JM. Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther. 2009;8:1438–47.

9. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Comput Methods Programs Biomed. 2011;101(1):72–9.

10. Holford, N. VPC, the visual predictive check—superiority to standard diagnostic (Rorschach) plots. In: PAGE 2005. 2005.

11. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21:457–78.

12. Dansirikul C, Silber H, Karlsson M. Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn. 2008;35:269–83.

13. Iliadis A, Barbolosi D. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Comput Biomed Res. 2000;33:211–26.

14. Simeoni M, Magni P, Cammia C, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64:1094–101.

15. Mita MM, Mita AC, Ricart A, et al. Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: Safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors. J Clin Oncol (Meeting Abstracts). 2006;24:3048.

16. Alghisi GC, Rüegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium. 2006;13:113–35.

17. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90:561–5.

18. Bueno L, de Alwis DP, Pitou C, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008;44:142–50.